Programmed cell death protein 1 (PD-1) blockade, which is successful in extranodal NK/T-cell lymphoma and EBV-related hemophagocytic lymphohistiocytosis, is considered to have a potential role in managing ANKL. This evidence concerns the gene PDCD1 and extranodal nasal NK/T cell lymphoma.